Literature DB >> 33225632

Amphiphilic Polyelectrolyte Graft Copolymers Enhance the Activity of Cyclic Dinucleotide STING Agonists.

Dinh Chuong Nguyen1,2, Daniel Shae1, Hayden M Pagendarm3, Kyle W Becker1, Mohamed Wehbe1, Kameron V Kilchrist3, Lucinda E Pastora1, Christian R Palmer1, Pedro Seber1, Plamen P Christov4, Craig L Duvall3, John T Wilson1,3,5,6,4,7,8.   

Abstract

Cyclic dinucleotide (CDN) agonists of stimulator of interferon genes (STING) hold great therapeutic potential, but their activity is hindered by poor drug-like properties that restrict cytosolic bioavailability. Here, this challenge is addressed through the synthesis and evaluation of a novel series of PEGMA-co-DEAEMA-co-BMA copolymers with pH-responsive, membrane-destabilizing activity to enhance intracellular delivery of the CDN, cGAMP. Copolymers are synthesized with PEGMA of two different molecular weights (300 and 950 Da) and over a range of PEG mass fraction and polymer molecular weight, and relationships between copolymer structure, self-assembly, endosomal escape, and cGAMP activity are elucidated. A subset of polymers that self-assembled into 50-800 nm nanoparticles is identified, which can be loaded with cGAMP via a simple mixing strategy, resulting in significantly enhanced immunostimulatory activity. Increased cGAMP activity is found to be highly correlated with the capacity of carriers to enhance intracellular CDN uptake and to promote endosomal destabilization, findings that establish efficient cytosolic delivery as a criterion for CDN carriers. Additionally, it is demonstrated that a lead CDN carrier formulation can enhance STING activation in vivo in a model of intratumoral immunotherapy. Collectively, these investigations demonstrate the utility of PEGMA-co-DEAEMA-co-BMA copolymers as carriers for CDNs and potentially other cytosolically-acting drug cargo.
© 2020 Wiley-VCH GmbH.

Entities:  

Keywords:  endosomal escape; graft copolymers; polymer nanoparticles; self-assembling nanoparticles; stimulator of interferon genes (STING)

Mesh:

Substances:

Year:  2020        PMID: 33225632      PMCID: PMC7856189          DOI: 10.1002/adhm.202001056

Source DB:  PubMed          Journal:  Adv Healthc Mater        ISSN: 2192-2640            Impact factor:   9.933


  38 in total

1.  Intracellular delivery system for antibody-Peptide drug conjugates.

Authors:  Geoffrey Y Berguig; Anthony J Convertine; Shani Frayo; Hanna B Kern; Erik Procko; Debashish Roy; Selvi Srinivasan; Daciana H Margineantu; Garrett Booth; Maria Corinna Palanca-Wessels; David Baker; David Hockenbery; Oliver W Press; Patrick S Stayton
Journal:  Mol Ther       Date:  2015-02-11       Impact factor: 11.454

2.  Overcoming transport barriers for interstitial-, lymphatic-, and lymph node-targeted drug delivery.

Authors:  Susan N Thomas; Alex Schudel
Journal:  Curr Opin Chem Eng       Date:  2015-02-01       Impact factor: 5.163

Review 3.  Pharmacological modulation of nucleic acid sensors - therapeutic potential and persisting obstacles.

Authors:  Claire Vanpouille-Box; Jules A Hoffmann; Lorenzo Galluzzi
Journal:  Nat Rev Drug Discov       Date:  2019-09-25       Impact factor: 84.694

4.  Employing bicontinuous-to-micellar transitions in nanostructure morphology for on-demand photo-oxidation responsive cytosolic delivery and off-on cytotoxicity.

Authors:  Sharan Bobbala; Sean D Allen; Sijia Yi; Michael Vincent; Molly Frey; Nicholas B Karabin; Evan A Scott
Journal:  Nanoscale       Date:  2020-03-05       Impact factor: 7.790

5.  Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma.

Authors:  Takashi Nakamura; Hiroko Miyabe; Mamoru Hyodo; Yusuke Sato; Yoshihiro Hayakawa; Hideyoshi Harashima
Journal:  J Control Release       Date:  2015-08-14       Impact factor: 9.776

6.  Ex vivo red blood cell hemolysis assay for the evaluation of pH-responsive endosomolytic agents for cytosolic delivery of biomacromolecular drugs.

Authors:  Brian C Evans; Christopher E Nelson; Shann S Yu; Kelsey R Beavers; Arnold J Kim; Hongmei Li; Heather M Nelson; Todd D Giorgio; Craig L Duvall
Journal:  J Vis Exp       Date:  2013-03-09       Impact factor: 1.355

Review 7.  Role of the cGAS-STING pathway in cancer development and oncotherapeutic approaches.

Authors:  Li Teng Khoo; Liuh-Yow Chen
Journal:  EMBO Rep       Date:  2018-11-16       Impact factor: 8.807

Review 8.  Agonists and inhibitors of the STING pathway: Potential agents for immunotherapy.

Authors:  Jun-Jun Wu; Lang Zhao; Hong-Guo Hu; Wen-Hao Li; Yan-Mei Li
Journal:  Med Res Rev       Date:  2019-12-02       Impact factor: 12.944

Review 9.  The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo.

Authors:  Hiroshi Maeda; Hideaki Nakamura; Jun Fang
Journal:  Adv Drug Deliv Rev       Date:  2012-10-23       Impact factor: 15.470

10.  Viromimetic STING Agonist-Loaded Hollow Polymeric Nanoparticles for Safe and Effective Vaccination against Middle East Respiratory Syndrome Coronavirus.

Authors:  Leon Chien-Wei Lin; Chen-Yu Huang; Bing-Yu Yao; Jung-Chen Lin; Anurodh Agrawal; Abdullah Algaissi; Bi-Hung Peng; Yu-Han Liu; Ping-Han Huang; Rong-Huay Juang; Yuan-Chih Chang; Chien-Te Tseng; Hui-Wen Chen; Che-Ming Jack Hu
Journal:  Adv Funct Mater       Date:  2019-04-12       Impact factor: 18.808

View more
  3 in total

Review 1.  Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy.

Authors:  Michael P Vincent; Justin O Navidzadeh; Sharan Bobbala; Evan A Scott
Journal:  Cancer Cell       Date:  2022-02-10       Impact factor: 31.743

Review 2.  Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy.

Authors:  Kyle M Garland; Taylor L Sheehy; John T Wilson
Journal:  Chem Rev       Date:  2022-02-02       Impact factor: 60.622

Review 3.  Immunostimulatory Polymers as Adjuvants, Immunotherapies, and Delivery Systems.

Authors:  Adam M Weiss; Samir Hossainy; Stuart J Rowan; Jeffrey A Hubbell; Aaron P Esser-Kahn
Journal:  Macromolecules       Date:  2022-08-04       Impact factor: 6.057

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.